Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Parishioners at Cathedral of the Holy Cross in the Boston’s South End gathered to pray for Pope Francis. WBZ-TV’s Logan Hall ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) last posted its earnings results on Monday, February 10th.

Edward Morrow Atkinson III, Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently sold a significant portion of his holdings in the ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

(Reuters) - Vertex Pharmaceuticals forecast annual revenue largely ... which treats a rare blood disorder requiring regular blood transfusions. The Boston, Massachusetts-based drugmaker developed ...